Who was studied?
Patients with knee pain received intra-articular BPC-157 alone or with thymosin beta-4; follow-up was by telephone.
- Participants
- 17 charts; 16 followed up
- Duration
- Variable; mostly 6–12 months
- Funding
- Private medical practice; funding not stated in the abstract
What did the study find?
Improvement was reported by 11 of 12 people in the BPC-only group and 3 of 4 in the combined group.
What should you keep in mind?
No control group or validated functional measures. Follow-up imaging was proposed rather than used to establish repair. The combination was described as thymosin beta-4, not verified as a particular TB-500 product.
Why it matters
Reported pain improvement does not establish tissue healing or validate another injection route.
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Published 2021 · PMID 34324435
Summary by Peptide Lit, checked against the original abstract on October 8, 2026. Read the complete paper for detailed methods and safety results. This page explains published research; it does not recommend a treatment or dose.